Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) dropped 7.1% during trading on Tuesday . The stock traded as low as $9.68 and last traded at $9.79. Approximately 266,163 shares were traded during trading, a decline of 73% from the average daily volume of 1,000,197 shares. The stock had previously closed at $10.54.
Analysts Set New Price Targets
VYGR has been the subject of several recent research reports. HC Wainwright initiated coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 19th. They set a "buy" rating and a $30.00 target price for the company. Guggenheim assumed coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 26th. They issued a "buy" rating and a $22.00 price target for the company. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $9.00 to $14.00 in a research report on Tuesday, January 2nd. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Thursday, March 7th. They issued a "buy" rating and a $16.00 target price for the company. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, March 9th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.33.
Get Our Latest Stock Analysis on VYGR
Voyager Therapeutics Stock Performance
The company's 50 day moving average price is $8.47 and its 200 day moving average price is $7.86. The company has a market cap of $538.11 million, a price-to-earnings ratio of 3.19 and a beta of 0.96.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, topping the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The company had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. On average, equities research analysts forecast that Voyager Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Voyager Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 2,529,668 shares of the company's stock valued at $21,350,000 after buying an additional 47,711 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Voyager Therapeutics by 27.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 180,025 shares of the company's stock worth $1,519,000 after purchasing an additional 38,906 shares during the last quarter. Barclays PLC grew its position in Voyager Therapeutics by 261.6% in the 4th quarter. Barclays PLC now owns 66,201 shares of the company's stock worth $559,000 after purchasing an additional 47,892 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in Voyager Therapeutics in the 4th quarter worth $1,526,000. Finally, Royal Bank of Canada grew its position in Voyager Therapeutics by 85.5% in the 4th quarter. Royal Bank of Canada now owns 12,017 shares of the company's stock worth $101,000 after purchasing an additional 5,540 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Featured Articles
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
